source
- FDA grants accelerated approval to first plasmid DNA immunotherapy for adult recurrent respiratory papillomatosisThe U.S. Food and Drug Administration granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) as a treatment for adults with recurrent respiratory pa…
- Moderna and Merck’s individualized cancer vaccine shows promising melanoma results but shares tumble after ESMO presentationInvestors closely watched the European Society for Medical Oncology (ESMO) meeting for updates on an individualized neoantigen cancer vaccine being co‑developed by Moderna and Merck. The therapy, c…BioPharma Dive · 10d agoPositive readoutNeutral